3 results
The primary objective is to determine the efficacy of pain control with this type of Peripheral Subcutaneous Field Stimulation (PSFS) at three months and 12 months. The secondary objectives determined at both 3 and 12 months are the assessment of…
To characterize safety, tolerability, pharmacodynamic effects, and pharmacokinetics of the oral sGC stimulator BAY 1021189 in addition to standard therapy for heart failure with reduced EF (HFrEF) over 12 weeks in patients with worsening chronic…
Main objectivePart A: To evaluate the safety and efficacy of treatment with VX-371, administered with and without 4.2% hypertonic saline (HS) in subjects with primary ciliary dyskinesia (PCD) who are *12 years of age.Part B: To evaluate the safety…